Pfizer Beats Q3 Estimates and Raises 2026 Outlook Despite COVID Revenue Decline

Pfizer delivered better-than-expected third-quarter results on Tuesday, prompting the pharmaceutical giant to raise its full-year 2026 outlook even as demand for its COVID-19 products continues to wane. The company reported adjusted earnings of 87 cents per share on revenue of $16.58 billion, easily surpassing Wall Street’s expectations of 73 cents per share and $15.87 billion in sales. The strong performance came despite revenue remaining essentially flat compared with the same quarter a year ago, when Pfizer generated $16.65 billion in sales.

The company now projects full-year revenue between $62 billion and $64 billion, up from its previous guidance of $60.5 billion to $62.5 billion. Pfizer also lifted its adjusted profit forecast to between $2.95 and $3.05 per share, compared with prior expectations of $2.80 to $3.00 per share. The low end of the revised sales range would represent roughly flat or slightly lower performance compared with 2025 revenue of $62.6 billion, yet Pfizer cited its “strong year-to-date performance” as justification for the upward revision.

New CFO Takes the Helm

Alongside its financial results, Pfizer announced the appointment of Cecile Guegan as its new chief financial officer and executive vice president, effective November 1. Guegan, who joined Pfizer through its 2009 acquisition of Wyeth, has held various finance leadership roles at the company over the past two decades. She most recently served as Senior Vice President of Finance for Pfizer’s Global Biopharmaceuticals business and had been acting as interim CFO since August, when former CFO Dave Denton departed to assume the same position at Nike.

The leadership transition comes as CEO Albert Bourla works to engineer a comeback story for the pharmaceutical giant following its massive pandemic-era success. The company faces mounting pressure from declining COVID product demand and generic competitors threatening its biggest revenue generators. Bourla’s strategy centers on jumpstarting growth through strategic acquisitions, fresh cancer drugs, and a significant bet on weight loss treatments through its acquisition of Metsera.

COVID Revenue Continues Sharp Decline

Third-quarter revenue of $16.58 billion reflected an operational decrease of $57 million primarily driven by lower COVID revenues, along with a $15 million negative impact from foreign exchange fluctuations. Sales from Pfizer’s COVID shot Comirnaty, developed in partnership with BioNTech, fell $339 million, representing a 29% year-over-year decline. The company’s COVID pill Paxlovid experienced an even steeper drop, with revenue plummeting $771 million, marking a 63% year-over-year decrease.

Revenue from the Prevnar family of vaccines also disappointed, dropping $180 million, or 10%, mainly due to lower vaccination rates across the United States. The declines underscore the challenge Pfizer faces as it transitions away from pandemic-related revenue streams that once propelled the company to record heights during 2021 and 2022.

Key Products Drive Growth Momentum

Offsetting the COVID-related underperformance, Pfizer’s non-pandemic portfolio delivered robust growth that exceeded analyst expectations. The anticoagulant Eliquis, developed in collaboration with Bristol Myers Squibb, generated $513 million in additional revenue, reflecting 25% year-over-year growth. The cancer therapy Padcev performed even better, with sales surging $255 million and posting 55% year-over-year growth. These strong performances from newly launched and acquired products demonstrate the company’s success in diversifying its revenue base beyond COVID treatments.

“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value,” CEO Albert Bourla said ahead of the conference call.

One-Time Charge Impacts Bottom Line

The company’s third-quarter results included a one-time charge of $650 million, representing a negative impact of 10 cents per share, tied to its licensing and collaboration agreement with Chinese cancer drugmaker Innovent Biologics. Despite this charge, Pfizer’s adjusted earnings per share of 87 cents matched the prior year period and substantially exceeded the consensus estimate of 74 cents.

Aggressive Cost-Cutting Continues

To help offset sharp declines in COVID product sales, Pfizer expanded its multi-year cost-cutting efforts in August, now targeting approximately $9.7 billion in net savings through 2029. The aggressive restructuring program aims to streamline operations and improve efficiency as the company pivots toward its post-pandemic business model. This operational discipline contributed to the company’s ability to meet earnings expectations despite revenue headwinds from declining COVID product demand.

Strategic Focus on Future Growth

Bourla’s strategic vision for Pfizer’s future extends beyond cost-cutting to encompass transformative acquisitions and pipeline development. The company’s acquisition of Metsera represents a significant wager on the rapidly expanding weight loss treatment market, which analysts project could reach tens of billions of dollars in annual sales. Combined with investments in oncology through drugs like Padcev and strategic collaborations like the partnership with Innovent Biologics, Pfizer aims to establish multiple growth drivers that can compensate for expiring patents and generic competition affecting legacy products.

The raised guidance reflects management’s confidence in executing this strategy throughout the remainder of 2026. Pfizer stock inched lower in early trading Tuesday despite the earnings beat and guidance increase, suggesting investors remain cautious about the company’s long-term growth prospects. However, the consistent operational execution and commercial momentum demonstrated in the third quarter provide tangible evidence that Pfizer’s post-pandemic transformation continues to progress according to plan.